A Novel System for the Quantification of the ADCC Activity of Therapeutic Antibodies

Figure 5

Quantification of the ADCC activity of rituximab using RTU iLite effector cells and CD20⁺ target cells: Effect of incubation time. RTU iLite effector cells (1.2 × 10⁵ cells/well) and CD20⁺ target cells were mixed at an E:T ratio of 3 : 1 and incubated for 4, 6, or 18 hours at 37°C in the presence of increasing concentrations of rituximab prior to the addition of Nano-Glo Dual-luciferase reagent (Promega, Madison, WI) and the sequential determination of FL and NL activity. Results are expressed as FL activity in RLU (a) or fold induction (b).